Supportive Care in Cancer

, Volume 18, Issue 8, pp 1081–1087 | Cite as

A systematic review of dysgeusia induced by cancer therapies

  • Allan J. Hovan
  • P. Michele Williams
  • Peter Stevenson-Moore
  • Yula B. Wahlin
  • Kirsten E. O. Ohrn
  • Linda S. Elting
  • Fred K. L. Spijkervet
  • Michael T. Brennan
  • Dysgeusia Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO)
Review Article

Abstract

Purpose

The purpose was to review relevant scientific papers written since 1989 which focused on the prevalence and management of dysgeusia as an oral side effect of cancer treatment.

Methods

Our literature search was limited to English language papers published between 1990 and 2008. A total of 30 papers were reviewed; the results of 26 of these papers were included in the present systematic review. A structured assessment form was used by two reviewers for each paper. Studies were weighted as to the quality of the study design, and treatment recommendations were based on the relative strength of each paper.

Results

A wide range in reported prevalence of dysgeusia was identified with the weighted prevalence from 56–76%, depending on the type of cancer treatment. Attempts to prevent dysgeusia through the prophylactic use of zinc sulfate or amifostine have been of limited benefit. Nutritional counseling may be helpful to some patients in minimizing the symptoms of dysgeusia.

Conclusions

Dysgeusia is a common oral side effect of cancer therapy (radiotherapy, chemotherapy, or combined modality therapy) and often impacts negatively on quality of life. From the current literature, there does not appear to be a predictable way of preventing or treating dysgeusia.

Keywords

Dysgeusia Cancer therapy Amifostine 

Notes

Conflict of interest statement

None declared.

References

  1. 1.
    Bartoshuk LM (1990) Chemosensory alterations and cancer therapies. NCI Monogr 9:179–184PubMedGoogle Scholar
  2. 2.
    Amossan C et al (2003) Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the SMART (simultaneous modulated accelerated radiation therapy) boost technique. Int J Oncol Biol Phys 56(1):136–144Google Scholar
  3. 3.
    Batist G et al (2002) Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann Oncol 13:1259–1263CrossRefPubMedGoogle Scholar
  4. 4.
    Beale J et al (2003) A phase I clinical and pharmacological study of cis-diamminedichloro (2-methylpuridine) platinum II (AMD473). Br J Cancer 88:1128–1134CrossRefPubMedGoogle Scholar
  5. 5.
    Buntzel et al (1998) Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Support Care Cancer 6:155–160CrossRefPubMedGoogle Scholar
  6. 6.
    Denis et al (2003) Late toxicity results of the gortec 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys 55(1):93–98CrossRefPubMedGoogle Scholar
  7. 7.
    Epstein J et al (2001) Quality of life and oral function in patients treated with radiation therapy for head and neck cancer. Head and Neck 23:389–398CrossRefPubMedGoogle Scholar
  8. 8.
    Fu-Min F et al (2005) Changing quality of life in patients with advanced head and neck cancer after primary radiotherapy or chemoradiation. Oncology 68:405–413CrossRefGoogle Scholar
  9. 9.
    Fu-Min F et al (2004) Changes in quality of life of head-and-neck cancer patients following postoperative radiotherapy. Acta Oncol 43(6):571–578CrossRefGoogle Scholar
  10. 10.
    Febbo PG et al (2005) Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 11(14):5233–5240CrossRefPubMedGoogle Scholar
  11. 11.
    Hainsworth J et al (2002) Induction paclitaxel, carboplatin and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally-advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer J 8:311–321CrossRefPubMedGoogle Scholar
  12. 12.
    Halyard et al (2007) Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4). Int J Radiat Oncol Biol Phys 67(5):1318–1322PubMedGoogle Scholar
  13. 13.
    Halyard M (2009) Taste and smell alterations in cancer patients—real problems with few solutions. J Support Oncol 7(2):68–69PubMedGoogle Scholar
  14. 14.
    Heckmann SM et al (2005) Zinc gluconate in the treatment of dysgeusia—a randomized clinical trial. J Dent Res 84(1):35–38CrossRefPubMedGoogle Scholar
  15. 15.
    Hong JH et al (2009) Taste and odor abnormalities in cancer patients. J Support Oncol 7(2):58–65PubMedGoogle Scholar
  16. 16.
    Huang et al (2000) Symptom profile of nasopharyngeal cancer patients during radiation therapy. Cancer Pract 8(6):274–281CrossRefPubMedGoogle Scholar
  17. 17.
    Hughes PJ et al (2000) Dysphagia in treated nasopharyngeal cancer. Head Neck 22:393–397CrossRefPubMedGoogle Scholar
  18. 18.
    Just et al (2005) Confocal microscopy of the peripheral gustatory system: comparison between healthy subjects and patients suffering from taste disorders during radiochemotherapy. Laryngoscope 115:2178–2182CrossRefPubMedGoogle Scholar
  19. 19.
    Kearvell et al (2004) Acute radiation toxicity assessment of a 3-D conformal head and neck radiation treatment technique. Australas Radiol 48:358–363CrossRefPubMedGoogle Scholar
  20. 20.
    Kita T et al (2004) Multifactorial analysis on the short-term side-effects occurring within 96 hours after radioiodine-131 therapy for differentiated thyroid carcinoma. Ann Nucl Med 18(4):345–349CrossRefPubMedGoogle Scholar
  21. 21.
    Komaki et al (2004) Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58(5):1369–1377CrossRefPubMedGoogle Scholar
  22. 22.
    Lu et al (2005) Prospective phase II trial of concomitant boose radiotherapy for stage II nasopharyngeal carcinoma: an evaluation of response and toxicity. Laryngoscope 115:806–810CrossRefPubMedGoogle Scholar
  23. 23.
    Macquart-Moulin et al (2000) High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment? J Clin Oncol 18(4):754–764PubMedGoogle Scholar
  24. 24.
    Maisano R et al (2003) Is weekly docetaxel an active and gentle chemotherapy in treatment of metastatic breast cancer? Anticancer Res 23:1923–1930PubMedGoogle Scholar
  25. 25.
    Martin M et al (2006) Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granuloctye-colony stimulating factor to the TAC regimen. Ann Oncol 17:1205–1212CrossRefPubMedGoogle Scholar
  26. 26.
    Ohrn K et al (2001) Oral status during RT and CT: a descriptive study of patient experiences and the occurrence of oral complications. Support Care Cancer 9:247–257CrossRefPubMedGoogle Scholar
  27. 27.
    Ravasco P et al (2005) Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. Head and Neck 27:659–668CrossRefPubMedGoogle Scholar
  28. 28.
    Ripamonti C (1998) Taste alterations in cancer patients. J Pain Symptom Manage 16(6):349–351CrossRefPubMedGoogle Scholar
  29. 29.
    Rosenbluth B et al (2005) Intensity-modulated radiation therapy for the treatment of nonanaplastic thyroid cancer. Int J Radiat Oncol Biol Phys 63:1419–1426CrossRefPubMedGoogle Scholar
  30. 30.
    Steinback S et al (2009) Qualitative and quantitative assessment of taste and smell changes in patients undergoing chemotherapy for breast cancer or gynecologic malignancies. J Clin Oncol 27(11):1899–1905CrossRefGoogle Scholar
  31. 31.
    Van Poznak C et al (2001) Oral gossypol in the treatment of patients with refractory metastatic breatst cancer: a phase I/II clinical trial. Breast Cancer Res Treat 66:239–248CrossRefPubMedGoogle Scholar
  32. 32.
    Vosmik M et al (2006) IMRT with the use of simultaneous integrated boost in treatment of head and neck cancer: acute toxicity evaluation. Acta Med 49(3):167–173Google Scholar
  33. 33.
    Williams et al (2004) The effect of education in managing side effects in women receiving chemotherapy for treatment of breast cancer. Oncol Nurs Forum 31(1):E16–E23CrossRefPubMedGoogle Scholar
  34. 34.
    Winter et al (2004) Quality of life following resection, free flap reconstruction and postoperative external beam radiotherapy for squamous cell carcinoma of the base of tongue. Clin Otolaryngol 29:274–278CrossRefPubMedGoogle Scholar
  35. 35.
    Yamashita et al (2006) Relation between acute and late irradiation impairment of four basic tastes and irradiated tongue volume in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys 66(5):1422–1429PubMedGoogle Scholar
  36. 36.
    Brennan MT, Elting LS, Spijkervet FKL. Systematic reviews of oral complications from cancer therapies, Oral Care Study Group, MASCC/ISOO: methodology and quality of the literature. Support Care Cancer doi:10.1007/s00520-010-0856-3

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Allan J. Hovan
    • 1
  • P. Michele Williams
    • 1
  • Peter Stevenson-Moore
    • 2
  • Yula B. Wahlin
    • 3
  • Kirsten E. O. Ohrn
    • 4
  • Linda S. Elting
    • 5
  • Fred K. L. Spijkervet
    • 6
  • Michael T. Brennan
    • 7
  • Dysgeusia Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO)
  1. 1.Program in Oral Oncology/DentistryBC Cancer AgencyVancouverCanada
  2. 2.Department of DentistryVancouver General HospitalVancouverCanada
  3. 3.Department of PaedodonticsUniversity of UmeaUmeaSweden
  4. 4.School or Health and Social StudiesDalarna UniversityFalunSweden
  5. 5.Department of BiostatisticsThe University of Texas M.D. Anderson Cancer CenterHoustonUSA
  6. 6.Department of Oral & Maxillofacial SurgeryUniversity Medical Center Groningen, University of GroningenGroningenThe Netherlands
  7. 7.Department of Oral MedicineCarolinas Medical CenterCharlotteUSA

Personalised recommendations